Type(s) of biological therapy-Pembrolizumab Posts on Medivizor
Navigation Menu

Type(s) of biological therapy-Pembrolizumab Posts on Medivizor

Benefits of autologous hematopoietic stem cell transplantation after checkpoint inhibitor therapy in patients with relapsed/refractory Hodgkin lymphoma

Benefits of autologous hematopoietic stem cell transplantation after checkpoint inhibitor therapy in patients with relapsed/refractory Hodgkin lymphoma

Posted by on Oct 3, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated real-life benefits of autologous hematopoietic stem cell transplantation (ASCT) after immune checkpoint inhibitor (CPi) therapy in patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL). The authors found that ASCT can be an effective option after CPi therapy in such patients. Some background Some patients...

Read More

Evaluating pembrolizumab in Hodgkin lymphoma after transplantation

Evaluating pembrolizumab in Hodgkin lymphoma after transplantation

Posted by on Jul 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of patients with relapsed or unresponsive Hodgkin lymphoma after stem cell transplant. Researchers found that pembrolizumab was a safe and effective treatment when used in this way. Some background Hodgkin lymphoma is a cancer of the immune...

Read More

A review of the side-effects of Nivolumab (Opdivo) treatment for Hodgkin Lymphoma.

A review of the side-effects of Nivolumab (Opdivo) treatment for Hodgkin Lymphoma.

Posted by on Nov 16, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This paper summarised the side effects associated with the use of nivolumab (Opdivo) for the treatment of Hodgkin Lymphoma. The main finding was that patients treated with nivolumab may experience immune-related side effects. Some background Brentuximab vedotin (Adcetris) and stem cell transplant are often used to treat classical...

Read More

Does anti-PD1 therapy change the effectiveness of chemotherapy in unresponsive Hodgkin lymphoma?

Posted by on Jun 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor